Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone
Authors:
- Millicent G. A. BennettMBMillicent G. A. Bennett
- Ashley S. MeakinAMAshley S. Meakin
- Kimberley J. Botting-LawfordKBKimberley J. Botting-Lawford
- Youguo NiuYNYouguo Niu
- Sage G. FordSFSage G. Ford
- Michael P. MurphyMMMichael P. Murphy
- Michael D. WieseMWMichael D. Wiese
- Dino A. GiussaniDino A. Giussani
- Janna L. MorrisonJMJanna L. Morrison
Open Access
- 22 February 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 285
Abstract
Background/Objectives: In pregnancy threatened by preterm birth, antenatal corticosteroids (ACS) are administered to accelerate fetal lung maturation. However, they have side effects, including the production of reactive oxygen species that can impact cytochrome P450 (CYP) activity. We hypothesised that antioxidants could protect a fetus treated with ACS during gestation and prevent the programming of altered hepatic CYP activity in the offspring. The primary outcome of our study was the impact of different maternal treatments on the activity of hepatic drug-metabolising enzymes in offspring. Methods: At 100 ± 1 days gestational age (dGA, term = 147 dGA), 73 ewes were randomly allocated to the following: saline (5 mL IV daily 105–137 ± 2 dGA, n = 17), ACS (Dexamethasone (Dex); 12 mg IM at 115 and 116 dGA; n = 25), MitoQ (6 mg/kg MS010 IV, daily bolus 105–137 ± 2 dGA; n = 17) or Dex and MitoQ (Dex+MitoQ; n = 14). CYP activity and protein abundance were assessed using functional assays and Western blot. Results: Dex decreased the hepatic activity of fetal CYP3A (−56%, PDex = 0.0322), and 9 mo lamb CYP1A2 (−22%, PDex = 0.0003), CYP2B6 (−36%, PDex = 0.0234), CYP2C8 (−34%, PDex = 0.0493) and CYP2E1 (−57%, PDex = 0.0009). For all, except CYP1A2, activity returned to control levels with Dex+MitoQ in 9 mo lambs. In 9 mo lambs, MitoQ alone increased activity of CYP2B6 (+16%, PMitoQ = 0.0011) and CYP3A (midazolam, +25%, PMitoQ = 0.0162) and increased CAT expression (PMitoQ = 0.0171). Dex+MitoQ increased CYP3A4/5 activity (testosterone, +65%, PIntx < 0.0003), decreased CYP1A2 activity (−14%, PIntx = 0.0036) and decreased mitochondrial abundance (PIntx = 0.0051). All treatments decreased fetal hepatic DRP1, a regulator of mitochondrial fission (PDex = 0.0055, PMitoQ = 0.0006 and PIntx = 0.0034). Conclusions: Antenatal Dex reduced activity of only one CYP in the fetus but programmed the reduced activity of several hepatic CYPs in young adult offspring, and this effect was ameliorated by combination with MitoQ.Keywords
Funding Information
- British Heart Foundation (RG/17/8/32924, FT170100431)
- Australian Research Council (RG/17/8/32924, FT170100431)
- Australian Research Training Program Scholarship (RG/17/8/32924, FT170100431)
This publication has 85 references indexed in Scilit:
- Antenatal corticosteroids and perinatal outcome in late fetal growth restriction: analysis of prospective cohortUltrasound in Obstetrics & Gynecology, 2023
- Timing of antenatal steroid administration for imminent preterm birth: results of a prospective observational study in GermanyArchives of Gynecology and Obstetrics, 2022
- Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birthCochrane Database of Systematic Reviews, 2020
- Antenatal corticosteroids in preterm small-for-gestational age infants: a systematic review and meta-analysisAmerican Journal of Obstetrics & Gynecology MFM, 2020
- Associations Between Maternal Antenatal Corticosteroid Treatment and Mental and Behavioral Disorders in ChildrenJAMA, 2020
- Vitamin C supplementation in pregnancyCochrane Database of Systematic Reviews, 2015
- Vitamin E supplementation in pregnancyCochrane Database of Systematic Reviews, 2015
- Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008American Journal of Obstetrics and Gynecology, 2011
- A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's diseaseMovement Disorders, 2010
- Antenatal glucocorticoid therapy increases glucose delivery to cerebral circulations during acute hypoxemia in fetal sheep during late gestationAmerican Journal of Obstetrics and Gynecology, 2009